Oppenheimer analyst Leland Gershell reiterated a Buy rating on Recro Pharma (REPH) yesterday and set a price target of $10.00. The company’s shares closed last Monday at $1.98, close to its 52-week low of $1.49.
According to TipRanks.com, Gershell is a 1-star analyst with an average return of -1.3% and a 35.8% success rate. Gershell covers the Healthcare sector, focusing on stocks such as Milestone Pharmaceuticals, BioMarin Pharmaceutical, and Corbus Pharmaceuticals.
Recro Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $7.50.
See today’s analyst top recommended stocks >>
Based on Recro Pharma’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $15.52 million and GAAP net loss of $6.01 million. In comparison, last year the company earned revenue of $31.26 million and had a GAAP net loss of $2.84 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Recro Pharma, Inc. is a pharmaceutical company, which engages in the research and development of non-opioid therapeutics for the treatment of acute post operative pain. It operates through the Acute Care, and Contract Development and Manufacturing (CDMO) business segment. The Acute Care segment focuses on developing innovative products for hospital and related settings. The CDMO segment leverages the company’s formulation expertise to develop and manufacture pharmaceutical products using the company’s proprietary delivery technologies for commercial partners who commercialize or plan to commercialize these products. Its products include Meloxicam, Dexmedetomidine, and Fadolmidine. The company was founded by Geraldine A. Henwood and Thomas F. Henwood on November 15, 2007 and is headquartered in Malvern, PA.
